ArticleJournal of medical cases2022
Drug-Induced Liver Injury Secondary to Enobosarm: A Selective Androgen Receptor Modulator.
Article in Journal of medical cases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- Limitations of Molecular Docking in Predicting the Selectivity of Selective Androgen Receptor Modulators (SARMs): A Comparative Study of YK11 and Ostarine Across Five Nuclear Receptors.International journal of molecular sciences · 2026Article
- Drug-induced liver injury associated with selective androgen receptor modulators in an adolescent patient.JPGN reports · 2025Article
- In Vitro and In Vivo Human Metabolism of Ostarine, a Selective Androgen Receptor Modulator and Doping Agent.International journal of molecular sciences · 2024Article
- Selective androgen receptor modulator use and related adverse events including drug-induced liver injury: Analysis of suspected cases.European journal of clinical pharmacology · 2024Review
- An Ultra-High-Performance Liquid Chromatography Coupled with Tandem Mass Spectrometry Method with Online Solid-Phase Extraction Sample Preparation for the High-Throughput and Sensitive Determination of Ostarine in Human Urine.Methods and protocols · 2024Article
- Bile Cast Nephropathy Because of Acute Liver Injury Associated With Selective Androgen Receptor Modulators.ACG case reports journal · 2023Article
- Systematic Review of Safety of Selective Androgen Receptor Modulators in Healthy Adults: Implications for Recreational Users.Journal of xenobiotics · 2023Review
- Drug-induced Liver Injury from Hormonal and Non-hormonal Therapies: Insights from a Large Case Series.Journal of clinical and experimental hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selective androgen receptor modulators (SARMs) are compounds that bind to androgen receptors and have similar anabolic properties to anabolic steroids. Unlike anabolic steroids, which bind to androgen receptors in many tissues all over the body, individual SARMs selectively bind androgen receptors in certain tissues, but not in others. This selectivity has attracted researchers due to the possibility of using SARMs for the potential benefits of androgen receptor stimulation, such as increased muscle mass and increased bone density, while minimizing the adverse effects, such as erythrocytosis and hepatotoxicity. Enobosarm, a SARM, has been studied for use in treatment of cachexia, osteoporosis, breast and prostate cancers, and stress urinary incontinence. Enobosarm can be found in some over-the-counter muscle-building supplements. We report a 31-year-old man with no significant personal or family medical history who presented with itching and dark-colored urine for 1 week. Three weeks prior to presentation, he had begun using a muscle-building supplement containing enobosarm. Diagnostic workup concluded a drug-induced hepatocellular liver injury secondary to enobosarm, which subsequently improved after discontinuation of enobosarm-containing muscle-building supplement use. As enobosarm and other SARMs are increasingly found in the over-the-counter supplements and being studied for other clinical applications, it is important to recognize their potential for liver toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.